K
2162
vs
E
EPE
Over the past 12 months, KeyMed Biosciences Inc has significantly outperformed EPE, delivering a return of +53% compared to the EPE's 0% growth.
Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
Smart Verdict
AI-Powered
Let AI Decide.
Valuation Comparison
| Company | Last Price | Intrinsic Value | DCF Value | Relative Value | Wall St Target | ||
|---|---|---|---|---|---|---|---|
|
K
|
KeyMed Biosciences Inc
HKEX:2162
|
54
HKD
|
|||||
|
E
|
Epizyme Inc
F:EPE
|
559
EUR
|
|||||
Compare the stock's valuation with its competitors.
Growth Comparison
Growth Over Time
2162, EPE
Compare company's financials with its competitors.
| Company | LTM | Historical Growth | Growth Streak | % Positive Years | Max Drawdown | Volatility | Forecasted Growth | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | ||||||||
|
K
|
KeyMed Biosciences Inc
Revenue
|
|||||||||||
|
E
|
Epizyme Inc
Revenue
|
|||||||||||
All metrics are calculated based on data from the last 10 years.
Compare company's financials with its competitors.
Profitability Comparison
Free Cash Flow
2162, EPE
Compare company's free cash flow with its competitors.
| Company | LTM | Average | Historical Growth | FCF Margin | Conversion | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 3 Years | 5 Years | 10 Years | ||||||
|
K
|
KeyMed Biosciences Inc
HKEX:2162
|
|||||||||
|
E
|
Epizyme Inc
F:EPE
|
|||||||||
Compare company's free cash flow with its competitors.
Gross Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
K
|
KeyMed Biosciences Inc | ||||
|
E
|
Epizyme Inc | ||||
Operating Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
K
|
KeyMed Biosciences Inc | ||||
|
E
|
Epizyme Inc | ||||
Net Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
K
|
KeyMed Biosciences Inc | ||||
|
E
|
Epizyme Inc | ||||
FCF Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
K
|
KeyMed Biosciences Inc | ||||
|
E
|
Epizyme Inc | ||||
ROE
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
K
|
KeyMed Biosciences Inc | ||||
|
E
|
Epizyme Inc | ||||
ROA
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
K
|
KeyMed Biosciences Inc | ||||
|
E
|
Epizyme Inc | ||||
ROIC
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
K
|
KeyMed Biosciences Inc | ||||
|
E
|
Epizyme Inc | ||||
ROCE
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
K
|
KeyMed Biosciences Inc | ||||
|
E
|
Epizyme Inc | ||||
Solvency Comparison
Compare company's equity waterfall with its competitors.
Stocks Performance
Stocks Performance
2162, EPE
Performance Gap
2162, EPE
Performance By Year
2162, EPE
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
| FR |
|
Pharnext SCA
OTC:PNEXF
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
|
| US |
S
|
Seagen Inc
F:SGT
|
